Device-maker SPR Therapeutics raised $37 million in a Series D funding round led by Revelation Partners with participation from River Cities Capital and Mutual Capital Partners.
SPR plans to use the cash to speed the commercial use of its pain-relief device, the SPRINT Peripheral Nerve Stimulation System, fund clinical studies and invest in new technology.
“This additional funding will allow us...
Dr. Karen DeSalvo, formerly an acting assistant secretary for health at the Department of Health and Human Services and the chief of the Office of the National Coordinator for Health Information Technology, has joined digital venture platform LRVHealth as an executive advisor.
“My entire career has been focused on improving the health of people and communities by catalyzing solutions to address...
Editor's note: This article has been updated to clarify FDA classification of the Sprint Peripheral Nerve Stinulation system.
Cleveland, Ohio-based SPR Therapeutics announced today that it has received FDA clearance for a new version of its percutaneous, wearable pain management device.
With this 510(k) approval, the Sprint Peripheral Nerve Stimulation (PNS) system is now available as a single...
SPR Therapeutics, the Cleveland, Ohio-based developer of a wearable pain management device, announced yesterday the completion of $25 million in Series C financing. The company’s new funding — primarily secured from Frontcourt Ventures and an unnamed family office — will support commercialization of the Sprint Peripheral Nerve Stimulation System, and investigate its applicability across...
